Latest Oncology News

Updated ALLELE Data Confirm Clinical Benefit of Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

Updated ALLELE Data Confirm Clinical Benefit of Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease

April 2nd 2025

Courtney Flaherty

Tabelecleucel generated high response rates and favorable OS in patients with EBV-positive PTLD who had progressed on prior standard-of-care approaches.

Pacritinib Elicits Early Responses in Multi-Refractory Chronic Graft-Vs-Host Disease

Pacritinib Elicits Early Responses in Multi-Refractory Chronic Graft-Vs-Host Disease

April 2nd 2025

Kristi Rosa

Pacritinib was active and safe in patients with multi-refractory chronic graft-vs-host disease.

OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025

OncLive’s FDA Approval Report: The Regulatory Rundown for March 2025

April 2nd 2025

Kristi Rosa

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL

Axi-Cel Is Associated With Higher ORR, Increased CRS/ICANS vs Tisa-cel in Older Patients With R/R DLBCL

April 2nd 2025

Jax DiEugenio

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

Axatilimab After Second-Line Therapy Generates ORR Benefit in Steroid-Refractory cGVHD

Axatilimab After Second-Line Therapy Generates ORR Benefit in Steroid-Refractory cGVHD

April 2nd 2025

Ashley Chan

A consistent ORR was shown with axatilimab after second-line therapy, regardless of prior lines of therapy, in patients with steroid-refractory cGVHD.

Latest Oncology Videos

All Oncology News

ICANS, Corticosteroid Use Identified As Risk Factors for NRM-Associated Infections After Axi-Cel Infusion in R/R NHL

April 2nd 2025

Ashling Wahner

Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.

Brexu-Cel Demonstrates Efficacy, Safety in Older Patients with R/R Mantle Cell Lymphoma

April 2nd 2025

Chris Ryan

Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.

Orca-T Boosts cGVHD-Free Survival vs Allo-HSCT in Advanced Hematologic Malignancies

April 2nd 2025

Chris Ryan

Orca-T improved moderate-to-severe cGVHD–free survival vs conventional allogenic transplant in advanced hematologic malignancies.

Denosumab Biosimilars Earn Positive CHMP Opinion for Osteoporosis and Cancer-Related Bone Disease

April 2nd 2025

Courtney Flaherty

The EMA’s CHMP has issued a positive opinion for the denosumab biosimilars Osvyrti and Jubereq for the same indications as the reference products.

Silmitasertib Drives Disease Control in Advanced Basal Cell Carcinoma

April 2nd 2025

Chris Ryan

Silmitasertib generated disease control in patients with locally advanced or metastatic basal cell carcinoma.

Two MD Anderson Researchers Elected AAAS Fellows

April 2nd 2025

MD Anderson Cancer Center

Lung cancer clinician and prevention expert recognized for their achievements in advancing cancer care and research.

Revisit Every OncLive On Air Episode From March 2025

April 2nd 2025

Ashling Wahner

Read a recap of the episodes of OncLive On Air that aired in March 2025.

D-VRd Plus Daratumumab/Lenalidomide Maintenance Yields Favorable PFS Outcomes in High-Risk Myeloma

April 1st 2025

Ashling Wahner

D-VRd with daratumumab/lenalidomide maintenance led to sustained PFS and MRD negativity across high-risk subgroups of newly diagnosed multiple myeloma.

Cilta-Cel Significantly Boosts MRD Negativity Rates in Lenalidomide-Refractory Myeloma

April 1st 2025

Ashley Chan

Cilta-cel improved rates of MRD negativity and 30-month PFS vs SOC in patients with lenalidomide-refractory multiple myeloma with MRD negativity.

MDC-CAR-BCMA001 Shows Efficacy, Safety as Compassionate Use in R/R Multiple Myeloma and AL Amyloidosis

April 1st 2025

Courtney Flaherty

MDC-CAR-BCMA001 may be a suitable construct for the treatment of BCMA-pretreated patients with triple-class refractory multiple myeloma or AL amyloidosis.

Cilta-Cel Significantly Prolongs OS Vs SOC in Lenalidomide-Refractory Multiple Myeloma

April 1st 2025

Kristi Rosa

Ciltacabtagene autoleucel is the first CAR T-cell therapy to show significant OS benefit in multiple myeloma.

Comparative Analysis Shows ORR, OS Benefits With Obe-Cel in R/R B-ALL

April 1st 2025

Jax DiEugenio

Obe-cel showed higher response rates and longer survival vs non–CAR T therapies in adults with R/R B-ALL.

Inotuzumab Ozogamicin–Based Bridging Therapy Boosts Obe-Cel Outcomes in B-Cell ALL

April 1st 2025

Caroline Seymour

The addition of inotuzumab ozogamicin to bridging therapy led to high objective response rates and sustained survival in obe-cel recipients with B-cell ALL.

Donor-Derived CAR T-Cell Therapy Yields High CR Rate With Limited OS in T-Cell Lymphoma After Allo-HSCT Relapse

April 1st 2025

Chris Ryan

A donor-derived CAR T-cell therapy produced complete remissions, but survival was limited in relapsed/refractory T-cell lymphoma.

AFM28 Shows Preliminary Activity in CD123+ Relapsed/Refractory AML

April 1st 2025

Caroline Seymour

Stable disease was common in patients with CD123-positive, relapsed/refractory acute myeloid leukemia who were treated with AFM28.

See All News